physiology remains a growing part of modern cardiology. While technical innovation is a key factor in invasive electrophysiology (for both ablation and device therapy), understanding the mechanisms, natural course, and evaluation of arrhythmias is the cornerstone of progress. The year 2014 brought many novel insights and technical innovations, but also many large-scale studies and trials with relevance to clinical practice. The key findings of these studies are summarized and put into clinical perspective.
This review of accomplishments in arrhythmias and devices in 2014 is followed by a Current Opinion article entitled 'History taking as a diagnostic test in patients with syncope: developing expertise in syncope' by Wouter Wieling et al. 4 It focuses on the circumstances of transient losses of consciousness (T-LOC) within a comprehensive diagnostic work-up of such patients. Rightly so, the European Society of Cardiology Guidelines on syncope 5 recommend that the initial work-up of a suspected syncope should involve history taking, a physical examination, and an ECG as the circumstances of the event in particular usually provide high diagnostic yield. Surprisingly, there is relatively little research on how data from the medical history are collected and analysed in patients. The diagnostic yield of the initial work-up by non-expert physicians in T-LOC appears to be as high as 60-70%, with history taking the main factor, while, after standardized evaluation in dedicated divisions, up to 85% of the patients might receive a proper diagnosis. The diagnostic yield of expert history taking in patients undiagnosed after standardized approaches, however, is unknown. The Current Opinion article provided by Wieling et al. concentrates on the roles of evidence-based point scores and expert history taking in diagnosing suspected syncope.
The first original research paper on the topic, 'Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVER-ROES', by Thomas Vanassche et al. 6 is a subanalysis of the ACTIVE-A and AVERROES trials which investigated the AF pattern as a predictor of stroke. To that end, the authors analysed the rates of stroke and systemic embolism in 6563 aspirin-treated patients with AF. The CHA 2 DS 2 -VASc score was similar in patients with paroxysmal and persistent AF (3.1 + 1.4), but slightly higher in those with permanent AF (3.6 + 1.5, P , 0.001). Yearly ischaemic stroke rates were 2. In an age-and gender-matched cohort of 15 848 nonablated AF patients receiving rhythm control only, thrombo-embolic rates with and without OAC were 1.34 and 2.14, respectively. The adjusted incidence rate ratio was 0.53, thus favouring RFA as a treatment strategy. In summary therefore, thrombo-embolic risk beyond 3 months after RFA was low compared with matched non-ablated AF patients. Although the numbers were low overall, serious bleeding risk associated with OAC seems to outweigh the benefits of thrombo-embolic risk reduction. However, randomized studies are required in the future to corroborate these initial results. The editors of the European Heart Journal sincerely hope that these large cohorts from national registries and randomized trials will provide further insight to our readers into how to best manage patients with arrhythmias, and in particular atrial fibrillation.
